Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

65.45
-0.8000-1.21%
Post-market: 65.450.00000.00%19:30 EDT
Volume:1.74M
Turnover:114.39M
Market Cap:9.22B
PE:-28.66
High:66.80
Open:66.80
Low:65.09
Close:66.25
52wk High:95.49
52wk Low:34.38
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.85
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:19.80
PE(LYR):-5,367.83

Loading ...

Movement Alert|Arrowhead Pharmaceuticals Falls 6.35% in Pre-Market Trading, Trading at $66.86

Market Focus
·
Yesterday

Arrowhead Pharmaceuticals to Host R&D Webinar on ARO-MAPT Interim Phase 1/2a Data

Reuters
·
Sep 29

Arrowhead’s Plozasiran Trial Completion Marks a Key Catalyst in the Triglyceride Market

TIPRANKS
·
Sep 26

Arrowhead Pharmaceuticals Price Target Announced at $74.00/Share by Goldman Sachs

Dow Jones
·
Sep 24

Movement Alert|Arrowhead Pharmaceuticals Falls 6.92% in Regular Trading, Trading at $66.71

Market Focus
·
Sep 24

These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.

Dow Jones
·
Sep 23

Arrowhead Pharmaceuticals (ARWR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 22

Movement Alert|Arrowhead Pharmaceuticals Falls 5.41% in Regular Trading, Conservative Wording in Dual-Function RNAi Interim Data Extends Selling Pressure

Market Focus
·
Sep 17

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know

TradingKey
·
Sep 16

Movement Alert|Arrowhead Pharmaceuticals Falls 8.95% in Regular Trading, Interim Data for Dual-Function RNAi Therapy Triggers Sell-Off

Market Focus
·
Sep 16

Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA

TIPRANKS
·
Sep 15

Arrowhead Pharmaceuticals - Single Dose Escalation Completed Through 400 Mg; no Drug-Related Saes Reported

THOMSON REUTERS
·
Sep 15

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional Rnai Therapeutic for the Treatment of Mixed Hyperlipidemia

THOMSON REUTERS
·
Sep 15

Arrowhead Pharmaceuticals - Mean Maximal Non-Hdl Cholesterol Reduction of 61% with Single Dose

THOMSON REUTERS
·
Sep 15

Citi adds ‘upside 30-day catalyst watch’ on Arrowhead

TIPRANKS
·
Sep 09

Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target

MT Newswires Live
·
Sep 08

Arrowhead Pharmaceuticals : Citigroup Initiates Coverage with Buy Rating; Target Price $108

THOMSON REUTERS
·
Sep 08

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

Reuters
·
Sep 08

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05

Arrowhead Pharma to Present at Cantor Global Healthcare Conference

Reuters
·
Sep 03